Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

医学 免疫疗法 肿瘤科 内科学 肺癌 荟萃分析 危险系数 子群分析 癌症 置信区间
作者
Floris Dammeijer,Lysanne A. Lievense,G. Veerman,Henk C. Hoogsteden,Joost P. Hegmans,Lidia R. Arends,Joachim G.J.V. Aerts
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (26): 3204-3212 被引量:47
标识
DOI:10.1200/jco.2015.66.3955
摘要

Purpose Programmed cell death protein-1- checkpoint blockers have recently been approved as second-line treatment for advanced non–small-cell lung cancer (NSCLC). Unfortunately, only a subgroup of patients responds and shows long-term survival to these therapies. Tumor vaccines and cellular immunotherapies could synergize with checkpoint blockade, but which of these treatments is most efficacious is unknown. In this meta-analysis, we assessed the efficacy of tumor vaccination and cellular immunotherapy in NSCLC. Methods We searched for randomized controlled trials (RCTs) investigating cellular immunotherapy or vaccines in NSCLC. We used random effects models to analyze overall survival (OS) and progression-free survival (PFS), expressed as hazard ratios (HRs), and differences in time (months). The effect of immunotherapy type, disease stage, tumor histology, and concurrent chemotherapy was assessed using subgroup analysis and meta-regression. All procedures were performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results We identified 18 RCTs that matched our selection criteria; these included a total of 6,756 patients. Immunotherapy extended NSCLC survival and PFS, expressed as HR (OS: HR, 0.81, 95% CI, 0.70 to 0.94, P = .01; PFS: HR, 0.83, 95% CI, 0.72 to 0.95, P = .006) and month difference (OS: difference, 5.43 months, 95% CI, 3.20 to 7.65, P < .005; PFS: difference, 3.24 months, 95% CI, 1.61 to 4.88, P < .005). Cellular therapies outperformed tumor vaccines (OS as HR: P = .005, month difference: P < .001; PFS as HR: P = .001, month difference: P = .004). There was a benefit of immunotherapy in low-stage compared with high-stage NSCLC and with concurrent administration of chemotherapy only in one of four outcome measures evaluated (PFS in months: P = .01 and PFS as HR: P = .031, respectively). There was no significant effect of tumor histology on survival or PFS. Conclusion Tumor vaccines and cellular immunotherapies enhanced OS and PFS in NSCLC. Cellular immunotherapy was found to be more effective than tumor vaccination. These findings have implications for future studies investigating combination immunotherapy in NSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
机读卡完成签到,获得积分10
1秒前
weiCli完成签到,获得积分10
1秒前
1秒前
学术bug完成签到,获得积分20
2秒前
3秒前
Keep完成签到 ,获得积分10
4秒前
学术bug发布了新的文献求助10
5秒前
负责八宝粥完成签到,获得积分10
5秒前
所所的应助被wg采纳,获得10
5秒前
一颗苹果完成签到,获得积分10
6秒前
6秒前
酷波er的应助被稳重的秋天采纳,获得10
7秒前
ubless607的应助被ZHAOnit采纳,获得10
7秒前
12发布了新的文献求助10
7秒前
Solkatt发布了新的文献求助10
7秒前
SciGPT的应助被开心德地采纳,获得10
9秒前
开朗不凡发布了新的文献求助10
9秒前
9秒前
热心的巧荷完成签到,获得积分10
10秒前
11秒前
11秒前
12秒前
小马甲的应助被宿敌采纳,获得10
12秒前
orixero的应助被WLLLR采纳,获得10
13秒前
13秒前
lxl123完成签到 ,获得积分10
14秒前
郭鑫发布了新的文献求助10
15秒前
FashionBoy的应助被热心的巧荷采纳,获得10
15秒前
15秒前
科研通AI6.2的应助被单薄冰安采纳,获得10
15秒前
ai发布了新的文献求助10
16秒前
17秒前
林中鹿发布了新的文献求助10
17秒前
飞翔发布了新的文献求助10
17秒前
搜集达人的应助被开心德地采纳,获得10
17秒前
17秒前
平常南松发布了新的文献求助10
18秒前
19秒前
李梦晓发布了新的文献求助10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188654
求助须知:如何正确求助?哪些是违规求助? 9576372
关于积分的说明 21847161
捐赠科研通 7786741
什么是DOI,文献DOI怎么找? 3435402
关于科研通互助平台的介绍 2559632
邀请新用户注册赠送积分活动 2482360